Dabir, M.
Novruzov, E.
Mattes-György, K.
Beu, M.
Dendl, K.
Antke, C.
Koerber, S. A.
Röhrich, M.
Kratochwil, C.
Debus, J.
Haberkorn, U.
Giesel, F. L.
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Article History
Received: 23 May 2022
Revised: 23 May 2022
Accepted: 14 July 2022
First Online: 23 August 2022
Declarations
:
: The radiopharmaceuticals were used on an individual patient basis according to German Pharmaceuticals Act §13(2b). The patients gave written informed consent to receive the novel diagnostics and permitted anonymized publication of related medical data. The ethical committee of Heidelberg University approved this retrospective evaluation to be in accordance with the Helsinki declaration.
: U. H., C. K., and F. L. G. have a patent application for quinolone based FAP-targeting agents for imaging and therapy in nuclear medicine (EP 18155420.5). U. H., C. K., and F. L. G. have shares of a consultancy group for iTheranostics. F. L. G. is also advisor at ABX, Telix, SOFIE Biosciences and Alpha Fusion. S. A. K. received grants from View Ray Inc. and honoraria from IBA Dosimetry, outside the submitted work.